This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Quillivant XR

Emerging

Tris Pharma's once-daily 12-hour extended-release liquid methylphenidate, FDA-approved 2012 for pediatric ADHD ages 6-17.

Aliases (4)

Methylphenidate Hydrochloride Extended-Release Oral Suspension · MPH-XR liquid · LiquiXR methylphenidate · Tris Pharma Quillivant

TYPICAL DOSE

20 mg

Once daily AM

ROUTE

Oral (tablet)

Oral

CYCLE

No formal cycling protocol

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Quillivant XR?

Quillivant XR is an extended-release liquid formulation of methylphenidate, FDA-approved for ADHD in patients 6 years and older. It uses a proprietary multi-particulate suspension that allows once-daily dosing in liquid form for patients who can't swallow pills.

Key Benefits

Provides 12-hour ADHD symptom control with single morning dose, in liquid form ideal for pediatric or swallowing-difficulty populations. Improves attention, impulse control, and behavioral outcomes equivalent to other extended-release MPH formulations.

Mechanism of Action

Methylphenidate blocks dopamine and norepinephrine reuptake transporters (DAT/NET), increasing synaptic catecholamines in the prefrontal cortex and striatum. The XR formulation provides immediate-release plus delayed-release components for sustained plasma levels.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options3 known

MPH-XR liquidLiquiXR methylphenidateTris Pharma Quillivant

StatusSchedule II (US DEA) — Rx-required; brand-only as of 2026 (no AB-rated generic)

Peptide Interactions

Modafinil

Avoid

overlapping wakefulness/dopaminergic effects; would extend duration into evening and worsen sleep.

Bromantane

Avoid

overlapping dopaminergic effects; would amplify peak.

MAOIs (selegiline at >10mg, phenelzine, tranylcypromine)

Avoid

hypertensive crisis risk.

Caffeine at high doses

Avoid

additive cardiovascular load.

High-dose SSRIs / SNRIs

Avoid

serotonin syndrome theoretical risk.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Onset
~30-60 min from the immediate-release unbound fraction. Slightly faster perceived onset than Concerta tablets (liquid absorbs faster than the OROS shell's l…
Peak
~5-8 hours for the bulk of the resin-bound release. Similar afternoon-peak profile to Concerta.
Taper
10-14 hours post-dose. Same evening sleep-disruption issue as Concerta — residual drug + acute tolerance produces the "tired but wired" state at bedtime for…

Side Effects & Safety

Side effect profile is identical to Concerta and other long-acting methylphenidate formulations — see Concerta entry for full detail. Brief recap:

Common (>10%): Insomnia, decreased appetite, dry mouth, headache, weight loss (sustained use), abdominal pain, nausea, anxiety.
Less common (1-10%): Increased BP (~3-5 mmHg systolic typical), increased HR (~3-5 bpm typical), bruxism, tics (in tic-prone individuals), irritability, mood swings, sweating, dizziness.
Rare-serious (<1%):
- Cardiovascular events (MI, stroke, sudden cardiac death) — FDA boxed warning. Pre-existing structural heart abnormalities, arrhythmias contraindicated.
- Psychiatric reactions — new-onset psychosis, mania, severe anxiety. ~0.1-0.2% incidence; higher risk if personal/family history of bipolar or psychotic disorder.
- Priapism — rare but documented across methylphenidate class.
- Peripheral vasculopathy / Raynaud's phenomenon — methylphenidate-class effect.
- Serotonin syndrome — only with serotonergic agents (MAOIs, high-dose SSRIs, MDMA).
Quillivant-specific considerations: None unique to the formulation. The ion-exchange resin itself is biologically inert (used in cholestyramine and other GI products for decades). No GI obstruction concern (unlike Concerta's OROS shell with theoretical risk in narrow GI tracts). No "ghost tablet" since there's no shell.
Specific watch periods: First 2-4 weeks for psychiatric emergence, BP/HR titration. Long-term: annual cardiovascular check, growth monitoring in children/adolescents (the primary population).